CLR
Cellectar
Stock
Stock
ISIN: US15117F8077
Ticker: CLRB
US15117F8077
CLRB
Price
Price
CHART BY
Frequently asked questions
What is Cellectar's market capitalization?
The market capitalization of Cellectar is $13.51M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Cellectar?
Cellectar's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.513. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Cellectar's stock?
Currently, 3 analysts cover Cellectar's stock, with a consensus target price of $2.00. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Cellectar?
Cellectar's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$51.49M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Cellectar?
Cellectar has a free cash flow of -$47.69M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Cellectar have, and what sector and industry does it belong to?
Cellectar employs approximately 11 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Cellectar's shares?
The free float of Cellectar is 45.31M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $13.51M
- EPS (TTM)
- -$1.513
- Free Float
- 45.31M
- EBITDA (TTM)
- -$51.49M
- Free Cashflow (TTM)
- -$47.69M
Pricing
- 1D span
- $0.236$0.315
- 52W span
- $0.225$3.84
Analyst Ratings
The price target is $2.00 and the stock is covered by 3 analysts.
Buy
2
Hold
1
Sell
0
Information
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.
- Employees
- 11
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US15117F8077
- Primary Ticker
- CLRB
Knockouts
LSX Data · Fundamentals & EOD data from FactSet